Testing TQB3107 tablets in patients with advanced cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical study evaluates the safety and tolerability of TQB3107 tablets, a protein inhibitor designed to induce apoptosis and inhibit tumor cell proliferation, in patients with advanced malignancies. The study aims to identify dose-limiting toxicities, the maximum tolerated dose, and the recommended dose for future phases. Participants will be closely monitored to assess the drug's effects and overall safety profile.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 18 years ≤ age≤ 75 years (calculated from the date of signing the informed consent); Score 0\~1 point, estimated survival ≥ 3 months；
* Advanced malignant tumor；
* The major organs are functioning well；
* Negative serum pregnancy test within 7 days prior to the first dose and must be a non-lactating subject, female and male subjects of childbearing potential should agree to use contraception throughout the study and for 6 months after the study ends;
* Subjects voluntarily participated in this study, signing the informed consent form and demonstrating good compliance.

Exclusion Criteria:

* Hematologic malignancy has or is suspected to involve the central nervous system, or primary central nervous system lymphoma;
* Received any anti-cancer therapy such as major surgery, chemotherapy and/or radiotherapy, immunotherapy, or targeted therapy within 4 weeks prior to the first dose;
* Combined with severe or not well-controlled diseases, which the investigator judges to be at greater risk of entering this study；
* Those with a history of drug addiction or substance abuse；
* According to the judgment of the investigator, there are concomitant diseases that seriously endanger the safety of the subjects or affect the completion of the study, or subjects who are considered to be unsuitable for enrollment for other reasons.

Where it's running

• Sun Yat-sen University Cancer Cen
  Guangzhou, Guangdong, China Recruiting
• The Fifth Affiliated Hospital Sun Yat-sen University
  Zhuhai, Guangdong, China Recruiting
• The Affiliated Hospital of Chengde Medical College
  Chengde, Hebei, China Recruiting
• Harbin Medical University Cancer Hospital
  Harbin, Heilongjiang, China Recruiting
• Hunan Cancer Hospital
  Changsha, Hunan, China Recruiting
• The First People's Hospital Of Changzhou
  Changzhou, Jiangsu, China Recruiting

Study contacts

• Study coordinator: ZhiMing Li, Doctor
• Email: lzmsysu@163.com
• Phone: 13719189172

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• TQB2922 subcutaneous treatment for advanced cancers

  This Phase I test will try a new injectable drug, TQB2922, to see if it's safe and how the body handles it in adults with advanced non-squamous non-small cell lung cancer.

  Recruiting at 7 sites Phase 1 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Beijing, Beijing Municipality and 11 other locations · NCT07260708

• Personalized cancer treatment based on genomic analysis

  This study is testing whether personalized cancer treatments based on each patient's unique genetic makeup can improve outcomes for people with advanced cancers.

  Recruiting British Columbia Cancer Agency · Vancouver, British Columbia · NCT02155621

• TQF3250 Capsules in overweight and obese adults with limited weight loss from lifestyle changes

  This phase 1b study tests whether TQF3250 capsules are safe and tolerable, and whether they show preliminary signs of benefit, in adults with overweight or obesity who have not achieved enough weight loss with simple lifestyle changes.

  Recruiting at 6 sites Phase 1 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Beijing, Beijing Municipality and 9 other locations · NCT07798284

• TQF3250 capsules for adults with type 2 diabetes and overweight/obesity

  A small, early-phase study will test the safety and how the body handles different doses of TQF3250 pills in adults with type 2 diabetes who are overweight or obese.

  Recruiting Phase 1 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Fuzhou, Fujian and 11 other locations · NCT07747857

• GPC3-targeted ADC for advanced solid tumors

  This early-phase trial tests a Glypican-3 targeted antibody-drug conjugate (TQB6426) in adults with advanced cancers to see if it is safe and tolerable and to explore potential anti-tumor activity.

  Recruiting Phase 1 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Hefei, Anhui and 7 other locations · NCT07730190

• TQH3906 capsules vs warmer options in adults with moderate to severe plaque psoriasis

  This Phase 3 trial tests whether once-daily TQH3906 capsules can help adults with moderate to severe plaque psoriasis better than a placebo or the active drug deucravacitinib.

  Recruiting at 13 sites Phase 3 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Beijing, Beijing Municipality and 44 other locations · NCT07724366

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.